← Markets

IDEAYA Biosciences, Inc.

IDYA · NASDAQ

Market closed$36.01$0.080000 (+0.22%)After hours $36.50 · +1.36%

Key statistics

Previous close$35.93
Open$35.11
Day high$36.72
Day low$35.03
52-week high$40.58
52-week low$21.33
Market cap3.42B
Volume914.14K
Average volume1.14M
P/E ratio-22.51
Forward P/E—
EPS-1.60
Dividend yield0.00%

Market context

Why it moved

IDEAYA Biosciences edged higher after announcing that three darovasertib abstracts and one IDE849 abstract were accepted for poster presentation at the ESMO 2026 oncology congress, reinforcing investor confidence in the company's clinical pipeline progress in uveal melanoma.

InstagramStocktitanAbcnewsHklawInstagram

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026IDEAYA Biosciences closed essentially flat but edged higher in after-hours trading, buoyed by the company's announcement of four poster presentations at the ESMO 2026 Congress in Madrid (October 23–27), covering darovasertib data across its registrational Phase 2/3 OptimUM-02 trial and two additional uveal melanoma studies, as well as Phase 1 long-term results for IDE849—its DLL3-targeting ADC developed with Hengrui Pharma in SCLC. The ESMO news reinforces pipeline momentum following a $345M equity raise in June, with Hengrui targeting IDE849's first registrational trial initiation by year-end in both China and the U.S.

0.2227

July 14, 2026IDEAYA Biosciences closed up modestly during the regular session but is slipping about 2% in after-hours trading, diverging from a broadly supportive macro backdrop where cooler-than-expected June CPI (3.5%) lifted equities. The healthcare sector ETF (XLV) is holding essentially flat in extended hours, suggesting the after-hours pullback in IDEAYA is stock-specific rather than sector-driven. Investor focus for the biotech remains on its clinical pipeline following an earlier surge tied to Phase 2/3 cancer drug data, with the broader biotech sub-sector facing headwinds as Q2 earnings forecasts project a steep earnings decline for the group.

1.3831

July 14, 2026IDEAYA Biosciences declined amid a broad risk-off session as renewed U.S.-Iran military strikes rattled markets, sending oil prices surging ~5% and weighing on equities broadly. The XLV healthcare sector ETF also closed lower, with healthcare biotech names under particular pressure — FactSet projecting a ~79% Q2 earnings drop for the biotech sub-sector — though Goldman Sachs and Jim Cramer have recently highlighted biotech as a standout performer and prime M&A target in oncology. IDEAYA, an oncology-focused clinical-stage biotech, continues to attract investor attention around its pipeline catalysts and potential as an acquisition target in a sector where large-cap biopharma dealmaking is accelerating.

-2.2709

July 10, 2026IDEAYA Biosciences closed modestly lower, slipping below its recent trading range as biotech broadly emerged as a sector bright spot amid a cooling AI/semiconductor trade. Bullish analyst sentiment remains a key backdrop, with Truist maintaining a Buy and $63 price target, while RBC Capital reiterated Outperform despite trimming its target to $48 from $53. The company's recent inclusion in Russell Growth Benchmarks drove a 43% 30-day return, and a routine pre-planned insider sale of 9,550 shares by the CAO at ~$40 underscores the stock's strong recent run. Potential headwinds include upcoming Medicaid cuts from the 'One Big Beautiful Bill,' which analysts warn could dampen biotech revenue projections and investor appetite starting in 2027.

-0.7779

July 9, 2026IDEAYA Biosciences closed down nearly 2% as investors continued a 'sell the news' rotation following the stock's recent addition to several Russell Growth Benchmarks, which had fueled a sharp 43% rally over the prior month. Analyst sentiment remains broadly constructive—Truist holds a Buy with a $63 target and RBC Capital maintains an Outperform rating despite trimming its target from $53 to $48—while the broader healthcare sector continues to outperform. A pre-planned insider sale by the Chief Accounting Officer of ~9,550 shares drew attention, though it was executed under a Rule 10b5-1 plan and viewed as routine. IDEAYA's $323.6M equity raise provides a solid cash runway to advance its precision oncology pipeline with partners Roche and AstraZeneca.

-1.7914

July 9, 2026IDEAYA Biosciences tumbled roughly 6% in a classic 'sell the news' reaction after its recent addition to several Russell Growth Benchmarks triggered profit-taking following a sharp 43% rally over the prior month. RBC Capital maintained its Outperform rating but trimmed its price target to $48 from $53, while Truist held a Buy with a $63 target — reflecting mixed near-term caution despite long-term confidence. The broader market added headwinds, with a risk-off session driven by U.S.-Iran geopolitical escalation lifting oil prices and pressuring equities broadly.

-6.2947

July 7, 2026IDEAYA Biosciences rose nearly 3%, touching a fresh 52-week high of $40.58, as the oncology-focused biotech benefits from a favorable M&A backdrop and continued analyst support. RBC Capital maintained its Outperform rating today, though it trimmed its price target to $48 from $53, while Jim Cramer called biotech 'the hottest group in the market' on CNBC, citing a wave of pending M&A as the FDA regulatory environment turns more permissive—a backdrop that could benefit mid-cap biotechs like IDEAYA with promising late-stage pipeline assets targeting MTAP-deleted tumors.

2.8956

July 7, 2026IDEAYA Biosciences surged to a 52-week high, gaining over 85% in the past year, as investors responded to its recent inclusion in multiple Russell indexes — including the Russell 3000, 2500, and 2000 — which broadens its institutional shareholder base and trading liquidity. The rally also reflects growing optimism around the company's NDA filing for darovasertib plus crizotinib, targeted for the second half of 2026 under the FDA's Real-Time Oncology Review framework, representing the most significant near-term regulatory catalyst for this precision oncology biotech.

4.5684

Stock Titan · July 17, 2026IDEAYA melanoma data and partner Hengrui's lung cancer results head to ESMOPR Newswire · July 17, 2026IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical ProgramsPR Newswire · June 10, 2026IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesStock Titan · June 9, 2026IDEAYA sets $27 price in $300M stock and warrant sale to investorsPR Newswire · June 8, 2026IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded WarrantsStock Titan · June 8, 2026IDEAYA Biosciences plans up to $300M stock, warrant sale, plus $45M optionPR Newswire · May 5, 2026IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdateInvesting.com · April 14, 2026Guggenheim raises Ideaya Biosciences stock price target on trial data
Benzinga · July 17, 2026IDEAYA Biosciences Announces Presentations At 2026 European Society of Medical Oncology Meeting October 23-27, Providing Updates Across IDEAYA's Clinical Pipeline
Mt Newswire · July 9, 2026Ideaya Biosciences Insider Sold Shares Worth $382,131, According to a Recent SEC Filing
Benzinga · July 7, 2026RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48
Mt Newswire · July 7, 2026RBC Capital Adjusts IDEAYA Biosciences Price Target to $48 From $53, Maintains Outperform Rating
Mt Newswire · June 17, 2026IDEAYA Biosciences Elects CEO Yujiro Hata as Chairman
Mt Newswire · June 15, 2026IDEAYA Biosciences' Phase 1 Clinical Trial of Lung, Pancreatic Cancer Treatment Enrolls First Patient
Benzinga · June 15, 2026Ideaya Biosciences Enrolls First Patient In Its Phase 1 Trial Of IDE892 In Combination With IDE397 In Mtap-deleted Pancreatic And Lung Cancers
Benzinga · June 12, 2026Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target

Peers

S&P 500SPX · $7,457.69-1.01%Tango Therapeutics, Inc.TNGX · $28.56+3.33%Immunocore Holdings plcIMCR · $34.96+1.42%Syndax Pharmaceuticals, Inc.SNDX · $22.80+0.40%Black Diamond Therapeutics, Inc.BDTX · $1.79-1.10%Zymeworks Inc.ZYME · $24.190.00%Iovance Biotherapeutics, Inc.IOVA · $5.00+7.30%AMC Robotics CorporationAMCI · $5.05-1.56%Veracyte, Inc.VCYT · $59.13-0.15%Beam Therapeutics Inc.BEAM · $27.53-3.03%Galectin Therapeutics Inc.GALT · $4.18-1.18%